BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 121 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 0.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $29,115,550 | +30.2% | 4,710,277 | +7.0% | 0.00% | +50.0% |
Q1 2024 | $22,356,476 | -12.4% | 4,400,271 | +3.3% | 0.00% | -33.3% |
Q4 2023 | $25,524,572 | -7.8% | 4,260,638 | +8.9% | 0.00% | 0.0% |
Q3 2023 | $27,693,915 | +2.6% | 3,911,077 | +2.0% | 0.00% | 0.0% |
Q2 2023 | $26,981,196 | -11.5% | 3,832,555 | +4.9% | 0.00% | -25.0% |
Q1 2023 | $30,470,668 | +76469.1% | 3,653,556 | +5.4% | 0.00% | -33.3% |
Q4 2022 | $39,795 | -99.9% | 3,466,550 | +3.0% | 0.01% | 0.0% |
Q3 2022 | $42,409,000 | +22.1% | 3,365,844 | +2.5% | 0.01% | +20.0% |
Q2 2022 | $34,725,000 | -34.9% | 3,282,157 | +0.0% | 0.01% | -28.6% |
Q1 2022 | $53,364,000 | +19.7% | 3,281,978 | +2.0% | 0.01% | +40.0% |
Q4 2021 | $44,575,000 | -1.2% | 3,218,476 | +2.5% | 0.01% | -16.7% |
Q3 2021 | $45,114,000 | -8.3% | 3,139,499 | +0.9% | 0.01% | -14.3% |
Q2 2021 | $49,209,000 | +61.8% | 3,112,562 | +4.1% | 0.01% | +40.0% |
Q1 2021 | $30,413,000 | +53.7% | 2,990,523 | +12.6% | 0.01% | +66.7% |
Q4 2020 | $19,788,000 | +135.7% | 2,656,129 | +8.7% | 0.00% | +50.0% |
Q3 2020 | $8,394,000 | -20.3% | 2,443,712 | +10.5% | 0.00% | 0.0% |
Q2 2020 | $10,533,000 | +139.1% | 2,210,753 | +0.3% | 0.00% | +100.0% |
Q1 2020 | $4,406,000 | -66.6% | 2,203,678 | -42.3% | 0.00% | 0.0% |
Q4 2019 | $13,180,000 | +210.2% | 3,820,808 | +157.6% | 0.00% | 0.0% |
Q3 2019 | $4,249,000 | -24.6% | 1,483,362 | -0.2% | 0.00% | 0.0% |
Q2 2019 | $5,634,000 | -47.7% | 1,486,599 | +12.2% | 0.00% | -66.7% |
Q1 2019 | $10,781,000 | -45.6% | 1,324,509 | -46.1% | 0.00% | 0.0% |
Q4 2018 | $19,816,000 | +132.1% | 2,455,526 | +119.4% | 0.00% | +50.0% |
Q3 2018 | $8,537,000 | +48.5% | 1,118,978 | +11.5% | 0.00% | 0.0% |
Q2 2018 | $5,750,000 | +37.4% | 1,003,496 | +14.3% | 0.00% | +100.0% |
Q1 2018 | $4,186,000 | +4.1% | 877,651 | +7.1% | 0.00% | 0.0% |
Q4 2017 | $4,023,000 | +2.7% | 819,415 | +9.6% | 0.00% | 0.0% |
Q3 2017 | $3,918,000 | +7.7% | 747,750 | +14.2% | 0.00% | 0.0% |
Q2 2017 | $3,639,000 | -44.0% | 654,584 | -15.3% | 0.00% | -66.7% |
Q1 2017 | $6,493,000 | +98.4% | 773,115 | +49.5% | 0.00% | +50.0% |
Q4 2016 | $3,273,000 | +48.6% | 517,140 | +3.5% | 0.00% | +100.0% |
Q3 2016 | $2,202,000 | +57.2% | 499,502 | +1.2% | 0.00% | 0.0% |
Q2 2016 | $1,401,000 | -1.3% | 493,440 | -1.7% | 0.00% | 0.0% |
Q1 2016 | $1,419,000 | -71.2% | 501,983 | +5.3% | 0.00% | -66.7% |
Q4 2015 | $4,919,000 | -1.3% | 476,652 | +9.1% | 0.00% | 0.0% |
Q3 2015 | $4,982,000 | -17.8% | 437,068 | +7.6% | 0.00% | 0.0% |
Q2 2015 | $6,061,000 | +72.6% | 406,016 | +4.4% | 0.00% | +50.0% |
Q1 2015 | $3,512,000 | -31.2% | 389,008 | -7.4% | 0.00% | -33.3% |
Q4 2014 | $5,106,000 | +25.2% | 419,905 | +0.7% | 0.00% | 0.0% |
Q3 2014 | $4,079,000 | -13.3% | 417,177 | +13.0% | 0.00% | 0.0% |
Q2 2014 | $4,705,000 | +59.6% | 369,040 | +32.4% | 0.00% | +50.0% |
Q1 2014 | $2,948,000 | +75.1% | 278,664 | +25.7% | 0.00% | +100.0% |
Q4 2013 | $1,684,000 | +12.6% | 221,635 | +7.8% | 0.00% | 0.0% |
Q3 2013 | $1,496,000 | +458.2% | 205,526 | +19.1% | 0.00% | – |
Q2 2013 | $268,000 | – | 172,599 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |